AAP
MCRB icon

Arax Advisory Partners’s Seres Therapeutics MCRB Stock Holding History

Arax Advisory Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$18 – 5243
2026
Q1 		$18 Buy
6
+4
+200% +$47 ﹤0.01% 3723
2025
Q4 		$30 Hold
2
– – ﹤0.01% 3994
2025
Q3 		$38 Buy
+2
New +$32 ﹤0.01% 3545

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Arax Advisory Partners's MCRB Position: Q2 2026 in Review

Arax Advisory Partners sold out of Seres Therapeutics (MCRB) in Q2 2026, closing a stake of 6 shares — an estimated $18 sold.

Arax Advisory Partners first reported a position in MCRB in Q3 2025 and held it in 3 quarters. The position peaked at $38 in Q3 2025. 35 funds tracked by Wall St. Rank hold MCRB as of Q2 2026.

  • Arax Advisory Partners reported no remaining Seres Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 6 Seres Therapeutics shares in Q2 2026, an estimated $18.
  • Arax Advisory Partners first reported a position in Seres Therapeutics in Q3 2025 and held it in 3 quarters.
  • Arax Advisory Partners's Seres Therapeutics position peaked at $38 in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.